Artiva Biotherapeutics, Inc. (ARTV) stock intrinsic value fair value estimate & owner earnings analysis

Artiva Biotherapeutics is a clinical-stage cell therapy company developing AlloNK, an off-the-shelf, allogeneic natural killer (NK) cell therapy given together with the antibody rituximab, as a potential treatment for autoimmune diseases including refractory rheumatoid arthritis, Sjogren's disease and systemic sclerosis. The company has no approved products and no product revenue today. As of June 30, 2026, Artiva held approximately $349 million in cash and short-term investments and carries no debt. A large stock offering completed earlier in 2026 extended the company's cash runway, by its own account, into 2029 -- beyond the expected readout of its next major clinical trial. Roughly three months of spending have passed since that balance-sheet date, so today's cash position is closer to an estimated $325-330 million, or about $6.70 per share on the current 48.9 million shares outstanding. Because Artiva earns no revenue, the usual measure of ongoing cash generation is structurally negative: cash used in operations was $47 million in 2023, $55 million in 2024 and $77 million in 2025, funding research, clinical trials and administration rather than any revenue-producing activity. Two earlier partnerships that once brought in cash have both ended -- a collaboration with Merck that paid Artiva $30 million upfront in 2021 was terminated by Merck in 2023, and a collaboration with Affimed was terminated in 2025 after Affimed itself filed for insolvency. Neither continues today, and no partner payments are assumed going forward. The company's lead program, AlloNK in refractory rheumatoid arthritis, has real supporting evidence behind it: in a company-sponsored early-stage study, 71% of evaluable patients achieved a meaningful clinical response (ACR50) at six months, safety has been clean across 55 treated patients with none of the severe inflammatory or neurological side effects seen with some other cell therapies, and the FDA has granted the program its Regenerative Medicine Advanced Therapy designation, reflecting the agency's own view that the early data and unmet medical need justify an expedited path. The FDA has aligned with Artiva on a randomized, roughly 150-patient Phase 3 trial in refractory rheumatoid arthritis expected to begin in the second half of 2026, with results expected around the end of 2028. Earlier-stage data in Sjogren's disease and systemic sclerosis look similarly encouraging but are less far along. The company itself has plainly flagged the key risk here: its early data comes from a smaller, open-label study testing several diseases at once, and there is no guarantee the larger, controlled Phase 3 trial -- testing one disease in its own defined patient population -- will show the same magnitude of benefit. That is the central uncertainty in this story, and it will not be resolved for more than two years. In the bear case, the Phase 3 trial fails to confirm the earlier signal. Because the company is already funded well past the 2028 readout, this does not force a distressed stock sale, and shareholders are left with roughly what remains of the cash after funding the trial through to its conclusion -- worth an estimated $2 per share. In the base case, the Phase 3 trial generally confirms a benefit consistent with the strength of the earlier data and the FDA's own vote of confidence, though because that earlier study was smaller and less rigorously controlled, only part of the ultimate value is credited today -- an estimated $5 per share. In the bull case, the Phase 3 trial confirms the magnitude of the early results, the expedited designation shortens the path to approval, and AlloNK becomes the first approved cell therapy for refractory rheumatoid arthritis, with the Sjogren's disease and systemic sclerosis programs adding further value behind it -- an estimated $10 per share. Because this is a single binary clinical-trial outcome that will not read out for more than two years, a wide margin of safety is appropriate even though the balance sheet itself is not at risk. The margin-of-safety price is near $2.50 -- close to the bear case and well below the base case; from that price the base case implies a substantial gain, while the bear case implies a modest loss.